Pruritus · patients with chronic kidney disease (CKD) pruritus
1 finding from 1 review
Quality of life ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
Summary of findings table ‐ Topical capsaicin may leads to higher risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
PruritusScale from: 0 to 10 · participants with cholestatic pruritus (CP)
1 finding from 1 review
Quality of life ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · health problem or population
Summary of findings table ‐ GABA‐analogues showed no clear difference in risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · participants with cholestatic pruritus (CP)
Summary of findings table ‐ Naltrexone may leads to higher risk for at least one adverse event per patient compared with placebo (low certainty).
1 finding from 1 review
Pruritus · participants with cholestatic pruritus (CP)
1 finding from 1 review
Quality of life ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · participants with cholestatic pruritus (CP)
It is very uncertain whether summary of findings table ‐ Rifampin/rifampicin changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Pruritus: significant improvement · participants with cholestatic pruritus (CP)
It is very uncertain whether summary of findings table ‐ Flumecinol changes pruritus: significant improvement compared with placebo (very low certainty).
1 finding from 1 review
Pruritus · participants with cholestatic pruritus (CP)
1 finding from 1 review
Quality of life · participants with cholestatic pruritus (CP)
1 finding from 1 review
Patient satisfaction ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found